Evaxion A/S Files July 2025 6-K Report

Ticker: EVAX · Form: 6-K · Filed: 2025-07-17T00:00:00.000Z

Sentiment: neutral

Topics: reporting, sec-filing, registration-statement

TL;DR

Evaxion A/S filed a 6-K on 7/17/25, incorporating previous filings. Keep an eye on their ongoing disclosures.

AI Summary

Evaxion A/S filed a Form 6-K on July 17, 2025, to report information for the month of July 2025. This filing incorporates by reference previous registration statements on Forms S-8 and F-3, as well as multiple Form F-1 filings, indicating ongoing capital raising or reporting activities.

Why It Matters

This filing indicates ongoing reporting and potential capital-raising activities by Evaxion A/S, which could impact investors' understanding of the company's financial and regulatory status.

Risk Assessment

Risk Level: low — This is a routine reporting form (6-K) that incorporates previous filings, not announcing new material events.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

This Form 6-K is a report of a foreign private issuer pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of July 2025.

What other SEC filings are incorporated by reference into this report?

This report incorporates by reference Evaxion A/S's registration statements on Form S-8 (File No. 333-255064), Form F-3 (File No. 333-265132), and multiple Form F-1 filings (File Nos. 333-266050, 333-276505, 333-279153, 333-283304).

What is Evaxion A/S's principal executive office address?

Evaxion A/S's principal executive offices are located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

Does Evaxion A/S file annual reports under Form 20-F or Form 40-F?

The filing indicates that Evaxion A/S files annual reports under cover of Form 20-F.

What was Evaxion A/S's former company name?

Evaxion A/S's former company name was Evaxion Biotech A/S, with a date of name change on October 14, 2020.

From the Filing

0001104659-25-068548.txt : 20250717 0001104659-25-068548.hdr.sgml : 20250717 20250717083032 ACCESSION NUMBER: 0001104659-25-068548 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 31 CONFORMED PERIOD OF REPORT: 20250717 FILED AS OF DATE: 20250717 DATE AS OF CHANGE: 20250717 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 251128953 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 BUSINESS PHONE: 4552656554 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 FORMER COMPANY: FORMER CONFORMED NAME: Evaxion Biotech A/S DATE OF NAME CHANGE: 20201014 6-K 1 tm2520858d1_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨ INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s (the “Company”) registration statements on Form S-8 (File No. 333-255064) , on Form F-3 (File No. 333-265132) , on Form F-1, as amended (File No. 333-266050) , Form F-1 (File No. 333-276505) , Form F-1 (File No. 333-279153) , Form F-1 (File No. 333-283304) , and Form F-3 (File No. 333- 285778) , including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Entry Into Material Agreements. As previously announced, on July 11, 2025, Evaxion A/S (“Evaxion”, or the “Company”) a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release that it has finalized a debt settlement agreement of €3.5 million out of Evaxion’s €7 million loan with European Investment Bank (“EIB”), upon the Company’s issuance to EIB of warrants (“Warrants”) for 38,450,000 ordinary shares of a nominal value of DKK 0.25 in the Company (“Ordinary Shares”) (the “Debt Settlement”). Debt Settlement Agreement, Warrant to Subscribe for Ordinary Shares and Amendment Agreement In connection with the Debt Settlement, the Company and EIB entered into a Debt Settlement Agreement, dated as of July 11, 2025, pursuant to which the Company and EIB agreed that the Company would issue warrants for 38,450,000 Ordinary Shares to EIB and EUR 3,500,000 of the Company’s EUR 7,000,000 loan with EIB would be cancelled (the “Debt Settlement Agreement”). The terms by which EIB subscribed for the ADSs were set forth in the Warrant to Subscribe for Ordinary Shares on July 11, 2025 (the “Warrant to Subscribe for Ordinary Shares”). The Company issued Warrants to EIB to subscribe for 38,450,000 Ordinary Shares, represented by 769,000 American Depositary Shares (“ADSs”). The Warrants are exercisable immediately upon issuance, expire in ten years and have an exercise price equal to DKK 0.25 per Ordinary Share. The terms by which the EIB loan was partially cancelled were reflected in the Amendment Agreement to the Finance Contract d

View on Read The Filing